201 related articles for article (PubMed ID: 32374476)
1. Race does not predict skeletal-related events and all-cause mortality in men with castration-resistant prostate cancer.
Patel DN; Howard LE; De Hoedt AM; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Klaassen ZW; Terris MK; Freedland SJ
Cancer; 2020 Jul; 126(14):3274-3280. PubMed ID: 32374476
[TBL] [Abstract][Full Text] [Related]
2. Factors predicting skeletal-related events in patients with bone metastatic castration-resistant prostate cancer.
Klaassen Z; Howard LE; de Hoedt A; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Freedland SJ
Cancer; 2017 May; 123(9):1528-1535. PubMed ID: 28026865
[TBL] [Abstract][Full Text] [Related]
3. Do skeletal-related events predict overall survival in men with metastatic castration-resistant prostate cancer?
Howard LE; De Hoedt AM; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Divers CH; Valderrama A; Freedland SJ
Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):380-384. PubMed ID: 27377207
[TBL] [Abstract][Full Text] [Related]
4. Predictors of skeletal-related events and mortality in men with metastatic, castration-resistant prostate cancer: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
Tablazon IL; Howard LE; De Hoedt AM; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Freedland SJ; Williams SB
Cancer; 2019 Nov; 125(22):4003-4010. PubMed ID: 31390061
[TBL] [Abstract][Full Text] [Related]
5. Race does not predict the development of metastases in men with nonmetastatic castration-resistant prostate cancer.
Whitney CA; Howard LE; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Freedland SJ
Cancer; 2016 Dec; 122(24):3848-3855. PubMed ID: 27505036
[TBL] [Abstract][Full Text] [Related]
6. Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy.
Francini E; Montagnani F; Nuzzo PV; Gonzalez-Velez M; Alimohamed NS; Rosellini P; Moreno-Candilejo I; Cigliola A; Rubio-Perez J; Crivelli F; Shaw GK; Zhang L; Petrioli R; Bengala C; Francini G; Garcia-Foncillas J; Sweeney CJ; Higano CS; Bryce AH; Harshman LC; Lee-Ying R; Heng DYC
JAMA Netw Open; 2021 Jul; 4(7):e2116536. PubMed ID: 34292336
[TBL] [Abstract][Full Text] [Related]
7. Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer.
Howard LE; Moreira DM; De Hoedt A; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Freedland SJ
BJU Int; 2017 Nov; 120(5B):E80-E86. PubMed ID: 28371163
[TBL] [Abstract][Full Text] [Related]
8. In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases? Results from the SEARCH Database.
Whitney CA; Howard LE; Posadas EM; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Freedland SJ
Eur Urol Focus; 2017 Oct; 3(4-5):480-486. PubMed ID: 28753787
[TBL] [Abstract][Full Text] [Related]
9. Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database.
Hanyok BT; Howard LE; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Posadas EM; Freedland SJ
Cancer; 2016 Jan; 122(2):222-9. PubMed ID: 26484853
[TBL] [Abstract][Full Text] [Related]
10. Risk of skeletal related events among elderly prostate cancer patients by site of metastasis at diagnosis.
Hussain A; Aly A; Daniel Mullins C; Qian Y; Arellano J; Onukwugha E
Cancer Med; 2016 Nov; 5(11):3300-3309. PubMed ID: 27730756
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen kinetics and outcomes in patients with bone metastases from castration-resistant prostate cancer treated with or without zoledronic acid.
Saad F; Segal S; Eastham J
Eur Urol; 2014 Jan; 65(1):146-53. PubMed ID: 22633317
[TBL] [Abstract][Full Text] [Related]
12. Age, Gleason Score, and PSA are important prognostic factors for survival in metastatic castration-resistant prostate cancer. Results of The Uroncor Group (Uro-Oncological Tumors) of the Spanish Society of Radiation Oncology (SEOR).
Valero J; Peleteiro P; Henríquez I; Conde A; Piquer T; Lozano A; Soler CC; Muñoz J; Illescas A; Jove J; Flores MM; Baquedano J; Diezhandino P; de Celis RP; Pardo EH; Samper P; Villoslada I; Eguiguren M; Millan V
Clin Transl Oncol; 2020 Aug; 22(8):1378-1389. PubMed ID: 31989474
[TBL] [Abstract][Full Text] [Related]
13. The Clinical and Economic Impacts of Skeletal-Related Events Among Medicare Enrollees With Prostate Cancer Metastatic to Bone.
McDougall JA; Bansal A; Goulart BH; McCune JS; Karnopp A; Fedorenko C; Greenlee S; Valderrama A; Sullivan SD; Ramsey SD
Oncologist; 2016 Mar; 21(3):320-6. PubMed ID: 26865591
[TBL] [Abstract][Full Text] [Related]
14. Racial Discrepancies in Overall Survival among Men Treated with
Zhao H; Howard LE; De Hoedt A; Terris MK; Amling CL; Kane CJ; Cooperberg MR; Aronson WJ; Klaassen Z; Polascik TJ; Vidal AC; Freedland SJ
J Urol; 2020 Feb; 203(2):331-337. PubMed ID: 31479407
[TBL] [Abstract][Full Text] [Related]
15. Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer.
Barlev A; Song X; Ivanov B; Setty V; Chung K
J Manag Care Pharm; 2010; 16(9):693-702. PubMed ID: 21067255
[TBL] [Abstract][Full Text] [Related]
16. The economic burden of skeletal-related events among elderly men with metastatic prostate cancer.
Jayasekera J; Onukwugha E; Bikov K; Mullins CD; Seal B; Hussain A
Pharmacoeconomics; 2014 Feb; 32(2):173-91. PubMed ID: 24435407
[TBL] [Abstract][Full Text] [Related]
17. Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer.
Fizazi K; Massard C; Smith M; Rader M; Brown J; Milecki P; Shore N; Oudard S; Karsh L; Carducci M; Damião R; Wang H; Ying W; Goessl C
Eur Urol; 2015 Jul; 68(1):42-50. PubMed ID: 25449207
[TBL] [Abstract][Full Text] [Related]
18. Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer - an Australian multi-centre observational study.
Anton A; Wong S; Shapiro J; Weickhardt A; Azad A; Kwan EM; Spain L; Gunjur A; Torres J; Parente P; Parnis F; Goh J; Semira MC; Gibbs P; Tran B; Pezaro C
Eur J Cancer; 2021 Nov; 157():485-492. PubMed ID: 34344533
[TBL] [Abstract][Full Text] [Related]
19. Predicting Time From Metastasis to Overall Survival in Castration-Resistant Prostate Cancer: Results From SEARCH.
Moreira DM; Howard LE; Sourbeer KN; Amarasekara HS; Chow LC; Cockrell DC; Pratson CL; Hanyok BT; Aronson WJ; Kane CJ; Terris MK; Amling CL; Cooperberg MR; Freedland SJ
Clin Genitourin Cancer; 2017 Feb; 15(1):60-66.e2. PubMed ID: 27692812
[TBL] [Abstract][Full Text] [Related]
20. Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events.
Smith MR; Coleman RE; Klotz L; Pittman K; Milecki P; Ng S; Chi KN; Balakumaran A; Wei R; Wang H; Braun A; Fizazi K
Ann Oncol; 2015 Feb; 26(2):368-74. PubMed ID: 25425475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]